146 related articles for article (PubMed ID: 21434951)
21. [Gastroesophageal reflux. Results of a multicenter study of 170 patients on the therapeutic value of the Gaviscon drinkable suspension].
Chevrel B
Med Chir Dig; 1980; 9(6):535-9. PubMed ID: 6259459
[No Abstract] [Full Text] [Related]
22. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
Guerre J; Neuman M; Bouchet J
Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
[No Abstract] [Full Text] [Related]
23. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux.
Mandel KG; Daggy BP; Brodie DA; Jacoby HI
Aliment Pharmacol Ther; 2000 Jun; 14(6):669-90. PubMed ID: 10848650
[TBL] [Abstract][Full Text] [Related]
24. Algicon in the management of gastro-oesophageal reflux.
Lambert JR; Korman MG; Nicholson L
Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
[No Abstract] [Full Text] [Related]
25. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children.
Forbes D; Hodgson M; Hill R
J Pediatr Gastroenterol Nutr; 1986; 5(4):556-9. PubMed ID: 3016226
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease.
Chatfield S
Curr Med Res Opin; 1999; 15(3):152-9. PubMed ID: 10621921
[TBL] [Abstract][Full Text] [Related]
27. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients.
Kwiatek MA; Roman S; Fareeduddin A; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2011 Jul; 34(1):59-66. PubMed ID: 21535446
[TBL] [Abstract][Full Text] [Related]
28. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.
Thomas E; Wade A; Crawford G; Jenner B; Levinson N; Wilkinson J
Aliment Pharmacol Ther; 2014 Mar; 39(6):595-602. PubMed ID: 24471505
[TBL] [Abstract][Full Text] [Related]
29. Gaviscon and domperidon responsive apnea episodes associated with gastro-esophageal reflux disease in twins.
Bilgin H; Eren A; Kara S
Asia Pac J Clin Nutr; 2015; 24(4):753-5. PubMed ID: 26693761
[TBL] [Abstract][Full Text] [Related]
30. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH.
Del Buono R; Wenzl TG; Ball G; Keady S; Thomson M
Arch Dis Child; 2005 May; 90(5):460-3. PubMed ID: 15851425
[TBL] [Abstract][Full Text] [Related]
31. Comparative study of Algicon versus Gaviscon in symptomatic gastro-oesophageal reflux.
Ward AE
Br J Clin Pract Suppl; 1989 Feb; 66():52-5; discussion 61-4. PubMed ID: 2556176
[No Abstract] [Full Text] [Related]
32. Gaviscon and gastroesophageal reflux in children.
Buts JP; Leclercq V
J Pediatr Gastroenterol Nutr; 1987; 6(3):482-3. PubMed ID: 2828595
[No Abstract] [Full Text] [Related]
33. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study.
De Ruigh A; Roman S; Chen J; Pandolfino JE; Kahrilas PJ
Aliment Pharmacol Ther; 2014 Sep; 40(5):531-7. PubMed ID: 25041141
[TBL] [Abstract][Full Text] [Related]
34. A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
Drug Dev Ind Pharm; 2018 Jan; 44(1):30-39. PubMed ID: 28836872
[TBL] [Abstract][Full Text] [Related]
35. Managing childhood gastro-oesophageal reflux.
Drug Ther Bull; 1997 Oct; 35(10):77-80. PubMed ID: 9489057
[No Abstract] [Full Text] [Related]
36. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients.
Sweis R; Kaufman E; Anggiansah A; Wong T; Dettmar P; Fried M; Schwizer W; Avvari RK; Pal A; Fox M
Aliment Pharmacol Ther; 2013 Jun; 37(11):1093-102. PubMed ID: 23600790
[TBL] [Abstract][Full Text] [Related]
37. [Restoration of the quality of life by eliminating and prevention of heartburn by alginate: results of multicenter study "VIA APIA"].
Lazebnik LB; Bordin DS; Masharova AA; Dzhulaĭ GS; Butov MA; Abdulkhakov RA; Eremina EIu; Tarasova LV; Safonova OV; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (6):70-6. PubMed ID: 20731169
[TBL] [Abstract][Full Text] [Related]
38. Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY
Aliment Pharmacol Ther; 2020 Jun; 51(11):1014-1021. PubMed ID: 32343001
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD].
Bordin DS; Masharova AA; Firsova LD; Kozhurina TS; Safonova OV
Eksp Klin Gastroenterol; 2009; (4):77-85. PubMed ID: 19960998
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic value of alginate test in gastroesophageal reflux disease].
Bordin DS; Masharova AA; Droxzdov VN; Firsova LD; Kozhurina TS
Eksp Klin Gastroenterol; 2010; (12):102-7. PubMed ID: 21560632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
